The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

Patrik Jonsson is an executive vice president at Eli Lilly and president of Lilly ... high-demand drugs now known as "weight-loss" shots: Mounjaro, prescribed for diabetes, and Zepbound, for ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

such as Zepbound and Mounjaro, over the last year. Eli Lilly on Thursday reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but it saw ...

Eli Lilly reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but saw lower realized prices. Demand in the U.S. has far outpaced supply ...